Search

Displaying results 2891 - 2900 of 10000 in total
  1. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). … TPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoietic lineages as well

    Categories: Thrombopoietin Receptor Agonist
  2. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    As cystinuria is a relatively rare disease, tiopronin is classified as an orphan drug and is not patented in the United States. … Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation.

  3. Drug

    Tacrine

    go.drugbank.com/drugs/DB00382
    ApprovedWithdrawn

    A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous

  4. Drug

    Esomeprazole

    go.drugbank.com/drugs/DB00736
    ApprovedInvestigational

    [A177571] Rapid discontinuation of PPIs such as esomeprazole may cause a rebound effect and a short term increase in hypersecretion. … Esomeprazole has been shown to inhibit acid secretion to a similar extent as [DB00338], without any significant differences between the two compounds _in vitro_.

    Products: EZOLIUM ®POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE, ESOZ 40 MG POLVO LIOFILIZADOPARA RECONSTITUIR A SOLUCION INYECTABLE
  5. Drug

    Pralatrexate

    go.drugbank.com/drugs/DB06813
    ApprovedInvestigational

    [A246703] As such, pralatrexate is thought to have a better therapeutic window compared to other antifolate analogs due to the novel target of RFC. … [A246693] Pralatrexate is designed to have a higher affinity for the reduced folate carrier, a protein that is overexpressed in malignant cells and is upregulated by oncogenes.

  6. Drug

    Sulfinpyrazone

    go.drugbank.com/drugs/DB01138
    Approved

    A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.

    Products: Nu-sulfinpyrazone Tab 200mg, Nu-sulfinpyrazone Tab 100mg
  7. Drug

    Chymopapain

    go.drugbank.com/drugs/DB06752
    ApprovedWithdrawn

    [L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982.

  8. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    [L48241,A232573] Pimavanserin was also under review as a potential treatment for dementia-related psychosis; however, as of April 2021, FDA approval has not been granted for this indication despite previous … Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders.

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists
  9. Target

    Integrin alpha-5

    go.drugbank.com/bio_entities/BE0008988
    TargetHumans

    ITGA5:ITGB1 is a receptor for IL1B and binding is essential for IL1B signaling (PubMed:29030430). … ITGA5:ITGB3 is a receptor for soluble CD40LG and is required for CD40/CD40LG signaling (PubMed:31331973).

    Synonyms: Fibronectin receptor subunit alpha
  10. Target

    Ephrin-B2

    go.drugbank.com/bio_entities/BE0010647
    TargetHumans

    Binds to receptor tyrosine kinase including EPHA4, EPHA3 and EPHB4. … The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling.

    Synonyms: EPH-related receptor tyrosine kinase ligand 5Function: ephrin receptor binding